Trial Profile
A Phase IIa/b Double-Blind, Randomised, Placebo-Controlled, Linear Trend Design Dose-Ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Intepirdine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 24 Dec 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record. (11 Dec 2006)
- 08 Feb 2010 Endpoint methodology added.
- 31 Jul 2008 Results were presented at the 12th International Conference on Alzheimer's Disease and Related Disorders.